Welcome to our dedicated page for Movano news (Ticker: MOVE), a resource for investors and traders seeking the latest updates and insights on Movano stock.
Movano Inc. (Nasdaq: MOVE), operating as Movano Health, is a health-focused technology company dedicated to revolutionizing the way we manage and monitor our health metrics. Founded in 2018 and headquartered in Pleasanton, California, Movano is committed to developing healthcare solutions that bring medical-grade, high-quality data to consumer health devices. The company's flagship product, the Evie Ring, is a wearable designed specifically for women to track a comprehensive array of health metrics including resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, and skin temperature variability. It also monitors period and ovulation tracking, menstrual symptom tracking, steps, active minutes, calories burned, sleep stages and duration, and mood tracking.
Movano Health has made significant strides in advancing its Evie Ring technology, as evidenced by a recent hypoxia trial conducted in collaboration with the University of California, San Francisco (UCSF). The study confirmed that the accuracy of Evie's pulse oximeter exceeds FDA guidelines. This milestone underscores the company's objective to achieve FDA clearance for the Evie Med Ring, a medical-grade version of the wearable. The Evie Med Ring aims to provide a seamless blend of accessibility, personalization, and medical reliability, significantly differentiating itself from existing wellness solutions.
In addition to its technological advancements, Movano Health recently secured a strategic investment from a tier-one multi-billion dollar medical device company. This partnership, along with a $24 million capital raise, ensures financial stability and accelerates the commercialization of Movano's proprietary technologies. The company has also entered into agreements to explore future collaborations for the development and commercialization of their healthcare solutions.
Movano Health's commitment to innovation extends to strategic collaborations with prestigious institutions like MIT. The company’s Evie Ring is being utilized in the MAESTRO study to understand long COVID and chronic Lyme disease, providing continuous, reliable data that could reshape approaches to these debilitating conditions.
For more information on Movano Health and their latest updates, visit here.
Movano Inc. (NASDAQ:MOVE) reported its financial results for Q3 2021, highlighting a net loss of $5.2 million, or $0.16 per share, an improvement from a $5.7 million loss in Q3 2020. The company remains in the development stage, generating no revenue. Movano has initiated clinical testing for its first wearable device prototype and completed the tapeout of its single-chip solution, a significant development milestone. With $39.3 million in cash as of September 30, 2021, Movano is preparing to showcase its technology at CES 2022 and explore strategic partnerships.
Movano Inc. (NASDAQ: MOVE) announced its participation in the Bernstein CGM Disruptors Conference on November 19, 2021. CEO John Mastrototaro will engage in a virtual fireside chat discussing the future of continuous glucose monitoring systems and connected health solutions aimed at preventing chronic diseases. Movano, established in 2018, develops personalized health devices offering crucial data such as glucose and blood pressure, enhancing users' ability to manage their health effectively.
Movano Inc (NASDAQ:MOVE) will report its third quarter 2021 financial and operational results on November 11, 2021. The company specializes in health technology, creating devices aimed at optimizing individual health and managing chronic diseases. A conference call will take place at 2:00 p.m. PDT for a business update. Movano's devices aim to provide crucial health metrics, such as glucose and blood pressure data, tailored to user preferences. The press release highlights the company’s forward-looking statements, cautioning investors about inherent risks and uncertainties.
Movano Inc. (NASDAQ:MOVE) reported its second quarter 2021 financial results, reflecting a net loss of $4.7 million, or $0.15 per share, improved from a $4.9 million loss in Q2 2020. The company continues to advance its health technology, receiving IRB approval for clinical studies and aiming to launch a new wearable device prototype by late Q3 or early Q4 2021. Movano also holds $42.7 million in cash and investments as of June 30, 2021, a significant increase from $5.7 million at year-end 2020, signaling robust financial health for ongoing R&D.
Movano Inc. (NASDAQ:MOVE) will report its Q2 2021 financial results on August 12, 2021.
Management will host a conference call at 2:00 p.m. PDT (5:00 p.m. EDT) to discuss these results and provide a business update. The live webcast can be accessed on the investors section of Movano's website. Movano focuses on creating health technology devices aimed at optimizing health and managing chronic diseases.
Movano Inc. (NASDAQ:MOVE) has received IRB approval to conduct blood pressure studies using its wrist-worn prototype device. The Company will test up to 200 participants in segmented groups to gather data for enhancing algorithm development. Initial testing involved 45 participants, and the data collected will support future studies. Movano aims for Class II FDA clearance while developing affordable, non-invasive health monitoring devices for chronic disease management. The recent study marks a vital step in their journey to innovate health technology.
Movano Inc. (NASDAQ:MOVE) is set to join the Russell Microcap Index as of June 28, 2021, improving its visibility within the investment community. This addition signifies a critical milestone for the health technology company, known for developing devices that provide essential health data to manage chronic diseases. The Russell Indexes, with approximately $10.6 trillion in assets benchmarked against them, offer a substantial platform for growth and investment opportunities.
Movano Inc. (NASDAQ: MOVE) reported its Q1 2021 financial results, showcasing a net loss of $8.1 million, or $1.01 per share, up from a loss of $4.0 million in Q1 2020. The company raised $48.9 million through its IPO, which will support its research and development in wearable health tech. CEO Dr. John Mastrototaro highlighted the focus on addressing chronic diseases through innovative devices. Movano remains in the development stage, with no revenue generated during the quarter. Cash reserves increased significantly to $46.8 million by March 31, 2021.
Movano Inc (NASDAQ:MOVE) will announce its first quarter 2021 financial results on May 13, 2021, followed by a conference call at 2:00 p.m. PDT. The call will provide insights into the company’s operational performance and strategic direction. Movano focuses on creating innovative health devices aimed at managing chronic diseases and providing essential health data. The company aims to empower users with actionable insights to enhance their health journey. Investors can access the webcast through the company’s investor relations page.
Movano Inc. (NASDAQ:MOVE) announced that Dr. John Mastrototaro will become the new CEO starting April 1, 2021. Previously the COO of OrthoSensor, Inc., Dr. Mastrototaro possesses over 30 years of experience in the medical device sector, emphasizing diabetes management innovations. He will focus on advancing Movano's technology for non-invasive glucose and blood pressure monitoring. Founder Michael Leabman transitions to CTO, continuing on the Board. This leadership change aims to enhance Movano's growth trajectory and expertise in the health technology market.
FAQ
What is the current stock price of Movano (MOVE)?
What is the market cap of Movano (MOVE)?
What does Movano Inc. do?
What is the Evie Ring?
Has Movano Health conducted any clinical trials?
What recent investments has Movano Health secured?
What is the Evie Med Ring?
How does Movano's technology benefit the healthcare sector?
What partnerships has Movano Health formed?
What are the main features of the Evie Ring?
When was Movano Inc. founded?
Where can I find more information about Movano Health?
